Sampling the Lower Respiratory Tract
Unambiguous Diagnosis of Lung Infections
Exclusively samples lower respiratory tract
Ideally Suited for Molecular Diagnostics
Menu
Global burden 2019
Lower Respiratory Infections
489 Million Cases Annually
Major Burden on Health Care System
2.49 Million Deaths Annually
Most Deadly of All Communicable Diseases
97.2 Million DALYs Annually
Prime Cause of Disability-Adjusted Life Years
Unambiguous Diagnosis is Hampered by Conventional Sampling Methods
Better sample, lower burden!
Lower Respiratory Infections
Accurate Diagnosis is a Sampling Challenge
Limitation of Conventional Sampling
Conventional samples are inherently contaminated by commensal bacteria from upper respiratory tract.
Poor Sample, Poor Diagnosis
Contamination of upper respiratory tract leads to inaccurate diagnoses.
Accurate Diagnosis Enables Directed Therapy
Poor diagnosis potentially results in undesirable under- or over-treatment.
Xheal Sampling Technology Enables Directed Therapy
Better sample, lower burden!
Modular Breath Sampler
Sampling Site of Infection
Capturing pathogen-loaded aerosols originating from mucosal surfaces of the lower respiratory tract.
Enabling Molecular Diagnostics
Our sample carries no contamination making it ideally compatible with fast molecular diagnostics.
Allowing Directed Therapy
By enabling fast molecular diagnostics, our sample allows for diagnosis within the golden hour.
Get In touch
Leave us a message
Reinier Postlaan 2, 6525GC Nijmegen, The Netherlands
About
Xheal Diagnostics B.V. is a start-up company and spin-off of the Radboudumc focussed sampling innovations for the lower respiratory tract. Our proprietary exhaled breath sampling technology enables a timely and better diagnosis of lung infections and hence improves patient care.